Major molecular response induced by nilotinib as first line treatment in a LMC patient with intermediate Sokal risk
Autor: | Ursula Sessa, Maria Celentano, Stefano Rocco, Rossella Fabbricini, Olimpia Finizio, Vincenzo Mettivier |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2015 |
Předmět: | |
Zdroj: | Clinical Management Issues, Vol 6, Iss 2S, Pp 11-14 (2015) |
Druh dokumentu: | article |
ISSN: | 1973-4832 2283-3137 |
DOI: | 10.7175/cmi.v6i2S.1138 |
Popis: | Here we describe a case of a man with chronic myeloid leukemia at intermediate risk, according to the Sokal index. After cytoreduction with hydroxyurea, the patient started nilotinib at standard dose (600 mg/day) obtaining a complete haematological response after one month of treatment.After about 3 months the patient presented a complete cytogenetic response and after six months major molecular response (MR3). At nine months of treatment the patient presented a complete molecular response (MR4). |
Databáze: | Directory of Open Access Journals |
Externí odkaz: |